Pharmacoeconomic analysis of anti-angiogenic therapy for diabetic macular edema

Te purpose of the study is to assess the economic consequences of the use of various anti-VEGF drugs in patients with diabetic macular edema (DME).

Materials and methods. Te cost–effectiveness analysis and budget impact analysis was conducted from the payer perspective (health insurance system).

Results. In accordance to the results from RCT (Protocol T) aflibercept required a lower number of intravitreal injections (IVI) and laser coagulations for frst year and it has tendency for lower number of IVI for the second year of treatment that resulted in lower costs for aflibercept therapy by 122,819 rubles (12.7 %) per patient within frst 2 years (1st year – 66,632 rubles, 2nd year – 61,186 rubles) in comparison with ranibizumab. Te cost–effectiveness analysis showed that aflibercept is a “cost–effective” method of treating patients with DME compared to ranibizumab in Pro Re Nata (PRN) mode. Te budget impact analysis has shown savings for the health insurance system (12 million rubles) for the analyzed patient cohort (n = 100) with aflibercept in 2 years (1st year – 6.163 million rubles; 2nd year – 6.119 million rubles). Te analysis of “lost opportunities” in a cohort of 100 patients showed that the use of aflibercept in DME can free up to 216 hospitalizations within 2 years (109 cases in the 1st year and 107 in the 2nd year). As a result, about 14 patients with DME can be additionally treated with aflibercept for two years within a fxed budget.

Conclusion. Treatment of DME with aflibercept can save resources of health insurance system compared to use of ranibizumab.

1. Pearce I, et al. Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review. Diabetes Obes Metab. 2018 Oct 2. DOI: 10.1111/dom.13550

2. International Diabetes Federation. IDF Diabetes Atlas, 8th edition; 2017.

3. Zheng Y, He M, Congdon N. Te worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012 Sep-Oct;60(5):428—31. DOI: 10.4103/0301-4738.100542

4. Dedov II, SHestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes mellitus. 2018;21;3:144—159. (In Russ). DOI: 10.14341/DM9686

5. Dedov II, Shestakova MV, Vikulova, OK. (2015). National register of diabetes mellitus in Russian Federation. Diabetes mellitus. 2015;18(3):5—22. DOI: https://doi.org/10.14341/DM201535-22

6. Aston Group. Te program of clinical and epidemiological monitoring of diabetes in the territory of the Russian Federation. Analytical report for 2017. (In Russ).

7. Dedov II, Shestakova MV, Suntsov YI, et al. Federal targeted programme “Prevention and Management of Socially Signifcant Diseases (2007-2012)”: results of the “Diabetes mellitus” sub-programme. Diabetes mellitus. 2013;16(2S):1—48. DOI: https://doi.org/10.14341/2072-0351-3879

8. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes care. 2012; 35(3):556—64. DOI:10.2337/dc11-1909

9. Acan D, Calan M, Er D, Arkan T, et al. Te prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey. BMC Ophthalmolog. 2018;18(1):91. DOI: https://doi.org/10.1186/s12886-018-0753-y

10. Elaraoud I, Attawan A, Quhill F. Case series investigating the efcacy and safety of bilateral fluocinolone acetonide (Iluvien®) in patients with diabetic macular edema. Ophthalmol Ter. 2016 Jun;5(1):95—104. DOI: 10.1007/s40123-016-0045-7

11. Giocanti-Auregan A, Tadayoni R, Grenet T, et al. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol. 2016 Aug 9;16:142. DOI: 10.1186/s12886-016-0317-y

12. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010 Jul;26(7):1587— 97. DOI: 10.1185/03007995.2010.482503

13. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17. DOI: 10.1186/s40662-015-0026-2.

14. Bandello F, Cunha-Vaz J, Chong NV, et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond). 2012 Apr;26(4):485—93. DOI: 10.1038/eye.2011.337

15. Hariprasad SM, Mieler WF, Grassi M, et al. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008 Jan;92(1):89—92.

16. Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta?analysis.Cochrane Database Syst Rev. 2018 Oct 16;10:CD007419. DOI: 10.1002/14651858.

17. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016 Jun;123(6):1351— 9. DOI: 10.1016/j.ophtha.2016.02.022

18. McLeod E, Lovato E, Wittrup-Jensen, KU, Muston DR. (2015). Cost of Illness, Diagnosis and treatment patterns for Diabetic Macular Edema across 13 Countries. Value in Health. 18(3), A181. DOI: https://doi.org/10.1016/j.jval.2015.03.1046

19. Early Treatment Diabetic Retinopathy Study Research Group et al. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987 Jul;94(7):761—74.

20. Early Treatment of Diabetic Retinopathy Study Research Group et al. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal charactereistics at baseline. ETDRS report number 19. Arch Ophthalmol. 1995 Sep;113(9):1144—55.

21. Diabetic Retinopathy Clinical Research Network et al. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008 Sep;115(9):1447—9, 1449.e1-10. DOI: 10.1016/j.ophtha.2008.06.015

22. Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012 Jul;8(4):274—284. DOI: 10.2174/157339912800840523

23. Lavinsky D, Cardillo JA, Melo LA, et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011 Jun 17;52(7):4314—23. DOI: 10.1167/iovs.10-6828

24. Figueira J, Khan J, Nunes S, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically signifcant diabetic macular oedema. Br J Ophthalmol. 2009 Oct;93(10):1341—4. DOI: 10.1136/bjo.2008.146712

25. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch. Ophthalmol. [Internet]. 1985;103(12):1796–806.

26. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185—222. DOI: 10.1159/000458539

27. Te Royal College of Ophthalmologists’ clinical guidelines for diabetic retinopathy: a summary. Eye (Lond). 2013 Feb; 27(2): 285—287. DOI: 10.1038/eye.2012.287

28. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology. 2017.

29. Korobelnik JF, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Nov;121(11):2247—54. DOI: 10.1016/j.ophtha.2014.05.006

30. Mitchell P, et al. Te RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011 Apr;118(4):615—25. DOI: 10.1016/j.ophtha.2011.01.031

31. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya EHjlea (aflibercept) (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0bfff6c-97b4-486e-82df-5f7b43cc579b&t.

32. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Lucentis (ranibizumab) (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=910f363a-f4d6-4ac7-b92e-274cfda70261&t.

33. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185. DOI 10.1007/s10456-011-9249-6.

34. Order of the Government of the Russian Federation of 23 October 2017 № 2323-r. (In Russ).

35. Decree of the Government of the Russian Federation of 8 December 2017 № 1492 «O Programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2018 god i na planovyj period 2019 i 2020 godov» (In Russ).

36. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193—1203. DOI: 10.1056/NEJMoa1414264

37. Sugimoto M, Tsukitome H, Okamoto F, et al. Clinical preferences and trends of anti?vascular endothelial growth factor treatments for diabetic macular edema in Japan. J Diabetes Investig. 2018 Sep 11. DOI: 10.1111/jdi.12929

38. Ozkaya A, Ozveren M, Demircan A. Te real life data of ranibizumab use among the diabetic macular edema patients in Turkey: Documenting the improvement with clinical optimization during three consecutive years. Saudi J Ophthalmol. 2018 Jul-Sep;32(3):175—179. DOI: 10.1016/j.sjopt.2018.04.005

39. Best AL, Fajnkuchen F, Nghiem-Buffet S, et al. Treatment Efcacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting. J Ophthalmol. 2018 Apr 18;2018:4610129. DOI: 10.1155/2018/4610129

40. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789—801. DOI: 10.1016/j.ophtha.2011.12.039

41. Order of FGBU «TSEKKMP» of the Ministry of Health of Russia of 29 December 2017 №185-od «Metodicheskie rekomendacii po raschetu zatrat pri provedenii kliniko-ehkonomicheskih issledovanij lekarstvennyh preparatov» (In Russ).